Ordering HEPLISAV-B starts with a phone call

Ordering HEPLISAV-B starts with a phone call

Please call 1-84-HEPLISAV (1-844-375-4728).

HEPLISAV-B may only be ordered through authorized distributors. Please call between 8 AM to 8 PM EST, Monday through Friday.

You may also enroll in the HEPLISAV-B Purchase Program for discounted pricing.*

Syringe

1. Submit your information below and an Enrollment Letter will be sent to you at the email address provided.

All fields required, unless otherwise noted.

This is a required field.
This is a required field.
This is a required field.
This is a required field.
This is a required field.
This is a required field.
This is a required field.
This is a required field.

2. Complete the HEPLISAV-B Purchase Program Enrollment Letter

3. Fax completed form to 1-844-328-5825 or email to ContractOps@Dynavax.com

*Terms and Conditions of Sale

All orders and returns are subject to our Terms and Conditions of Sale.

INDICATION AND IMPORTANT SAFETY INFORMATION
INDICATION

HEPLISAV-B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older.

IMPORTANT SAFETY INFORMATION

Do not administer HEPLISAV-B to individuals with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of HEPLISAV-B, including yeast.

Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of HEPLISAV-B.

Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to HEPLISAV-B.

Hepatitis B has a long incubation period. HEPLISAV-B may not prevent hepatitis B infection in individuals who have an unrecognized hepatitis B infection at the time of vaccine administration.

The most common patient-reported adverse reactions reported within 7 days of vaccination were injection site pain (23%-39%), fatigue (11%-17%), and headache (8%-17%).

Please see full Prescribing Information.

Phone IconCall 1-84-HEPLISAV (1-844-375-4728) or order online.
Call to Order
INDICATION AND IMPORTANT SAFETY INFORMATION
INDICATION

HEPLISAV-B is indicated for prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older.

IMPORTANT SAFETY INFORMATION

Do not administer HEPLISAV-B to individuals with a history of severe allergic reaction (e.g., anaphylaxis) after a previous dose of any hepatitis B vaccine or to any component of HEPLISAV-B, including yeast.

Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of HEPLISAV-B.

Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to HEPLISAV-B.

Hepatitis B has a long incubation period. HEPLISAV-B may not prevent hepatitis B infection in individuals who have an unrecognized hepatitis B infection at the time of vaccine administration.

The most common patient-reported adverse reactions reported within 7 days of vaccination were injection site pain (23%-39%), fatigue (11%-17%), and headache (8%-17%).

Please see full Prescribing Information.